CA
NZ
UK
AU
IND
US
JBDI Holdings Limited filed a Form 6-K on November 4, 2026, disclosing the completion of its acquisition of 100% of Glorian Capital Ltd. for an aggregate consideration of $900,000,000, paid entirely through senior unsecured perpetual zero coupon convertible promissory notes.
Equator Beverage Company filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting financial results for both the three and nine months ended September 30, 2026.
Shoals Technologies Group, Inc. filed an 8-K on November 4, 2026, disclosing that it entered into an Agreement and Plan of Merger and Reorganization with Array Technologies, Inc., under which each Shoals share would be converted into 1.6931 shares of Array common stock.
Westlake Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, reporting a return to profitability in the third quarter compared to a significant loss in the same period a year earlier.
Westlake Chemical Partners LP (NYSE:WLKP) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter net income of $90,857 thousand and nine-month net income of $254,874 thousand.
Director Richard A. Kerley filed a Form 144 notice of proposed sale of securities with the SEC on November 4, 2026, disclosing plans to sell 459 shares of Cavco Industries, Inc. common stock through Charles Schwab Corp.
TuHURA Biosciences, Inc. (NASDAQ:HURA) announced on November 4, 2026, that it will present three poster presentations on its Delta Opioid Receptor (DOR) research at the 68th American Society of Hematology Annual Meeting and Exposition, scheduled for December 12-15, 2026, in New Orleans, Louisiana.
Clarivate Plc disclosed via an 8-K press release dated November 4, 2026, that its wholly-owned subsidiary Clarivate Science Holdings Corporation has commenced cash tender offers to purchase up to $500,000,000 aggregate principal amount of its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% …
Cullinan Therapeutics, Inc. filed a Current Report on Form 8-K on November 4, 2026, disclosing updated clinical data from its CLN-049 Phase 1 dose escalation trial in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome, ahead of a December presentation at …
SelectQuote, Inc. filed a Form 10-Q with the SEC on November 4, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $20,301 thousand for the three months ended on that date.
Please wait processing your request...